NCT05777824View on ClinicalTrials.gov

Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2027

Conditions
Head and Neck Cancer
Interventions
COMBINATION_PRODUCT

anti-PD-1 or PD-L1 antibody

immunotherapy maintenance with anti-PD-1 or PD-L1 antibody every three weeks for 13 cycles after radiotherapy

RADIATION

postoperative radiaotherapy

postoperative radiotherapy (60Gy or 50Gy)

Trial Locations (1)

51000

RECRUITING

National Cancer Center /National Clinical Research Center for Cancer/Cancer Hospital, CAMS & PUMC, Beijin

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER